Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma by Berdeja, J.G, Lin, Y, Raje, N, Siegel, D, Munshi, N, Turka, A, Lam, L.P, Quigley, M.T, Kochenderfer, J.N

Get full text

Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) by Savona, M.R, Garcia-Manero, G, Roboz, G.J, Walsh, K.J, Kropf, P.L, Issa, J.P, O’Connell, C.L, Tibes, R, Yee, K.W.L, Stock, W, Lunin, S, Berdeja, J.G, Naim, S, Hao, Y, Azab, M, Kantarjian, H

Get full text

Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients (Pts) with Multiple Myeloma (MM) Who Are Not Candidates for High Dose Chemotherapy by Berdeja, J.G, Bauer, T, Essell, J, Arrowsmith, E, Chu, L, Acs, P, Boccia, R.V, Flinn, I

Get full text

Carfilzomib (CFZ, Kyprolis® ), lenalidomide (LEN, Revlimid® ), and dexamethasone (DEX) (KRd) combined with autologous stem cell transplant (ASCT) shows improved efficacy compared w... by Jakubowiak, A.J, Griffith, K, Jasielec, J.K, Rosenbaum, C.A, Berdeja, J.G, Vij, R, Raje, N, Reece, D, Rosebeck, S, Gurbuxani, S, Dytfeld, D, Zimmerman, T.M

Get full text

Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: results from a multicenter phase 2 trial by Richardson, P.G, Bensinger, W.I, Huff, C.A, Costello, C.L, Lendvai, N, Berdeja, J.G, Anderson, L.D, Siegel, D.S, Jagannath, S, Laubach, J.P, Stockerl-Goldstein, K.E, Knapp, L, Kwei, L, Clow, F, Graef, T, Bilotti, E, Vij, R

Get full text

14LBA - Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma by Berdeja, J.G., Lin, Y., Raje, N., Siegel, D., Munshi, N., Turka, A., Lam, L.P., Quigley, M.T., Kochenderfer, J.N.

Get full text

60 - Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) by Savona, M.R., Garcia-Manero, G., Roboz, G.J., Walsh, K.J., Kropf, P.L., Issa, J.P., O’Connell, C.L., Tibes, R., Yee, K.W.L., Stock, W., Lunin, S., Berdeja, J.G., Naim, S., Hao, Y., Azab, M., Kantarjian, H.

Get full text

PF612 ONCE‐WEEKLY (70 MG/M2) VERSUS TWICE‐WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA by Moreau, P., Stewart, A.K., Dimopoulos, M.‐A., Siegel, D., Facon, T., Berenson, J., Raje, N., Berdeja, J.G., Orlowski, R.Z., Yang, H., Ma, H., Klippel, Z., Zahlten‐Kumeli, A., Mezzi, K., Iskander, K., Mateos, M.‐V.

Request full text

PF612 ONCE‐WEEKLY (70 MG/M2) VERSUS TWICE‐WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA by Moreau, P., Stewart, A.K., Dimopoulos, M.‐A., Siegel, D., Facon, T., Berenson, J., Raje, N., Berdeja, J.G., Orlowski, R.Z., Yang, H., Ma, H., Klippel, Z., Zahlten‐Kumeli, A., Mezzi, K., Iskander, K., Mateos, M.‐V.

Get full text